ARNA Discussion Board - From the thefly on ARNA - ARNA Discussion Board - InvestorVillage
ARNA Discussion Board
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: ARNA Discussion Board   /  Message Board  /  Read Message


Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  49518 of 51747  at  2/18/2020 1:49:06 PM  by


 In response to msg 49517 by  valuationguy
view thread

Re: From the thefly on ARNA

 DERM is selling off to Lilly for $1.1B after a phase 2B study.  Who would want herpes just to get rid of atopic dermatitis.   Not me.  
 The most common adverse events reported across the lebrikizumab 250mg Q2W, 250mg Q4W and 125mg Q4W dosing arms were upper respiratory tract infection (2.7%, 11.3% and 8.2%, respectively, vs. 5.8% for placebo), nasopharyngitis (12.0%, 2.5% and 5.5%, respectively, vs. 3.8% for placebo), headache (5.3%, 1.3% and 4.1%, respectively, vs. 5.8% for placebo) and injection site pain (5.3%, 3.8% and 0.0%, respectively, vs. 1.9% for placebo). Rates of herpes viral infections (which includes oral herpes, herpes zoster, genital herpes, herpes simplex, and eczema herpeticum) were 2.7%, 5.0% and 2.7%, respectively, vs. 3.8% for placebo) and conjunctivitis (2.7%, 3.8% and 1.4%, respectively, vs. 0.0% for placebo) were low. Across all studies of lebrikizumab conducted to date in atopic dermatitis, conjunctivitis has been reported at low rates similar to those in patients receiving placebo.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 304
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
49520 Re: From the thefly on ARNA Bioimmuno 1 2/18/2020 3:02:41 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by